CAPTOR THERAPEUTICS SPOLKA AKCYJNA |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 79.8 PLN | -0.25% |
|
-0.50% | -19.39% |
| Sales 2023 * | 20.3M 5.05M | Sales 2024 * | 52.5M 13.06M | Capitalization | 372M 92.47M |
|---|---|---|---|---|---|
| Net income 2023 * | -76M -18.91M | Net income 2024 * | 6M 1.49M | EV / Sales 2023 * | 15.2 x |
| Net cash position 2023 * | 62.5M 15.55M | Net cash position 2024 * | 42.8M 10.65M | EV / Sales 2024 * | 6.26 x |
| P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | 111 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 50.65% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.48% | ||
| 1 week | -2.91% | ||
| Current month | +26.98% | ||
| 1 month | +29.03% | ||
| 3 months | -18.70% | ||
| 6 months | -23.44% | ||
| Current year | -19.19% |
1 week
79.20
82.00
1 month
59.0083.40
Current year
59.00102.00
1 year
59.00165.00
3 years
59.00209.00
5 years
59.00209.00
10 years
59.00209.00
| Managers | Title | Age | Since |
|---|---|---|---|
Thomas Shepherd
CEO | Chief Executive Officer | - | - |
| Director of Finance/CFO | - | 21-05-31 | |
| Chief Tech/Sci/R&D Officer | 39 | 19-11-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | 20-04-07 | |
| Director/Board Member | - | 21-12-31 | |
| Chairman | 52 | 18-08-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 79.8 | -0.25% | 1 019 |
| 24-04-25 | 80 | -1.48% | 5,722 |
| 24-04-24 | 81.2 | 0.00% | 1,092 |
| 24-04-23 | 81.2 | +1.50% | 3,626 |
| 24-04-22 | 80 | -0.25% | 2,337 |
Delayed Quote Warsaw S.E., April 25, 2024 at 11:55 am EDT
More quotes
Captor Therapeutics SA is a Poland-based biopharmaceutical company, which specializes in the development of drugs that cause the targeted degradation of pathogenic proteins. The Company works in the field of neoplastic and autoimmune diseases for which there is no treatment option, or the available methods show therapeutic limitations. The Company covers aspects of early-stage drug development to deliver therapeutics for life-threatening and life-impairing diseases. The broadly applicable Optigrade tm Targeted Protein Degradation (TPD) platform allows for the creation of new drugs.
Calendar
2024-05-26
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
80
PLN
Average target price
115
PLN
Spread / Average Target
+43.75%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -19.19% | 92.17M | |
| +1.12% | 42.59B | |
| +6.77% | 40.65B | |
| +47.02% | 40.57B | |
| -11.96% | 26.77B | |
| +6.01% | 24.81B | |
| -24.92% | 18.17B | |
| -3.63% | 11.7B | |
| +27.16% | 12.05B | |
| +7.30% | 11.1B |
- Stock Market
- Equities
- CTX Stock
